GILEAD SCIENCES, INC

GILD
Delayed Quote. Delayed  - 07/01 04:00:00 pm
62.36USD +0.89%

Turn to zoom
Prev.62.3600
Open61.4700
High62.4300
Low61.2700
Volume5 190 224
Latest news
2d ago
3d ago
4d ago
4d ago
Chart GILEAD SCIENCES, INC.
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBearishBearish
Resistance65,065,064,9
Spread/Res.-4,1%-4,1%-3,9%
Spread/Supp.8,0%8,0%7,5%
Support57,757,758,0
Financials
Sales 2022 24 543 M - -
Net income 2022 4 227 M - -
Net Debt 2022 16 327 M - -
P/E ratio 2022 17,7x
Yield 2022 4,66%
Capitalization 78 219 M 78 219 M -
EV / Sales 2022 3,85x
EV / Sales 2023 3,78x
Nbr of Employees 14 400
Free-Float 99,9%
Company
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%)...
Sector :
Bio Therapeutic Drugs
Calendar :
2022-07-27 Earnings Release
Trading Rating :
Investor Rating :

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 62,36 $
Average target price 69,65 $
Spread / Average Target 11,7%